...
syre-img

Spyre Therapeutics Inc., Common Stock

SYRE

NSQ

$23.86

+$0.73

(3.16%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.36B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.22M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.91
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$17.83 L
$47.97 H
$23.86

About Spyre Therapeutics Inc., Common Stock

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSYRESectorS&P500
1-Week Return-1.08%-2.12%-3%
1-Month Return-13.24%-3.42%-0.73%
3-Month Return-20.91%-11.13%2.87%
6-Month Return-6.91%-5.74%7.17%
1-Year Return53.44%3.97%25.31%
3-Year Return-77.22%1.05%28.38%
5-Year Return-87.01%34.37%81.89%
10-Year Return-90.23%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue--18.74M2.33M886.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.43,"profit":true},{"date":"2023-12-31","value":4.73,"profit":true}]
Cost of Revenue901.00K1.62M2.00M1.96M964.00K[{"date":"2019-12-31","value":45.03,"profit":true},{"date":"2020-12-31","value":81.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.15,"profit":true},{"date":"2023-12-31","value":48.18,"profit":true}]
Gross Profit(901.00K)(1.62M)16.74M365.00K(78.00K)[{"date":"2019-12-31","value":-5.38,"profit":false},{"date":"2020-12-31","value":-9.7,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":2.18,"profit":true},{"date":"2023-12-31","value":-0.47,"profit":false}]
Gross Margin--89.32%15.67%(8.80%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.55,"profit":true},{"date":"2023-12-31","value":-9.86,"profit":false}]
Operating Expenses79.43M81.48M84.39M87.11M243.19M[{"date":"2019-12-31","value":32.66,"profit":true},{"date":"2020-12-31","value":33.51,"profit":true},{"date":"2021-12-31","value":34.7,"profit":true},{"date":"2022-12-31","value":35.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(80.33M)(81.48M)(65.65M)(84.78M)(242.30M)[{"date":"2019-12-31","value":-8033400000,"profit":false},{"date":"2020-12-31","value":-8148100000,"profit":false},{"date":"2021-12-31","value":-6564900000,"profit":false},{"date":"2022-12-31","value":-8478100000,"profit":false},{"date":"2023-12-31","value":-24230300000,"profit":false}]
Total Non-Operating Income/Expense3.56M1.18M100.00K1.67M(90.37M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":33.19,"profit":true},{"date":"2021-12-31","value":2.81,"profit":true},{"date":"2022-12-31","value":46.85,"profit":true},{"date":"2023-12-31","value":-2539.8,"profit":false}]
Pre-Tax Income(78.25M)(80.89M)(65.66M)(83.95M)(338.82M)[{"date":"2019-12-31","value":-7825400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6566000000,"profit":false},{"date":"2022-12-31","value":-8395100000,"profit":false},{"date":"2023-12-31","value":-33881600000,"profit":false}]
Income Taxes-(593.00K)141.00K(136.00K)(26.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-420.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-96.45,"profit":false},{"date":"2023-12-31","value":-18.44,"profit":false}]
Income After Taxes-(80.30M)(65.80M)(83.81M)(338.79M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8030000000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}]
Income From Continuous Operations(83.21M)(80.89M)(65.80M)(83.81M)(338.79M)[{"date":"2019-12-31","value":-8321400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(78.25M)(80.89M)(65.80M)(83.81M)(338.79M)[{"date":"2019-12-31","value":-7825400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}]
EPS (Diluted)(61.25)(40.25)(25.00)(25.33)(74.19)[{"date":"2019-12-31","value":-6125,"profit":false},{"date":"2020-12-31","value":-4025,"profit":false},{"date":"2021-12-31","value":-2500,"profit":false},{"date":"2022-12-31","value":-2533,"profit":false},{"date":"2023-12-31","value":-7419,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SYRE
Cash Ratio 7.20
Current Ratio 7.32

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SYRE
ROA (LTM) -38.81%
ROE (LTM) -91.62%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SYRE
Debt Ratio Lower is generally better. Negative is bad. 0.22
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.78

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SYRE
Trailing PE NM
Forward PE NM
P/S (TTM) 2209.92
P/B 7.91
Price/FCF NM
EV/R 1964.91
EV/Ebitda NM

FAQs

What is Spyre Therapeutics Inc. share price today?

Spyre Therapeutics Inc. (SYRE) share price today is $23.86

Can Indians buy Spyre Therapeutics Inc. shares?

Yes, Indians can buy shares of Spyre Therapeutics Inc. (SYRE) on Vested. To buy Spyre Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SYRE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Spyre Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Spyre Therapeutics Inc. (SYRE) via the Vested app. You can start investing in Spyre Therapeutics Inc. (SYRE) with a minimum investment of $1.

How to invest in Spyre Therapeutics Inc. shares from India?

You can invest in shares of Spyre Therapeutics Inc. (SYRE) via Vested in three simple steps:

  • Click on Sign Up or Invest in SYRE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Spyre Therapeutics Inc. shares
What is Spyre Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Spyre Therapeutics Inc. (SYRE) is $47.97. The 52-week low price of Spyre Therapeutics Inc. (SYRE) is $17.83.

What is Spyre Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Spyre Therapeutics Inc. (SYRE) is

What is Spyre Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Spyre Therapeutics Inc. (SYRE) is 7.91

What is Spyre Therapeutics Inc. dividend yield?

The dividend yield of Spyre Therapeutics Inc. (SYRE) is 0.00%

What is the Market Cap of Spyre Therapeutics Inc.?

The market capitalization of Spyre Therapeutics Inc. (SYRE) is $1.36B

What is Spyre Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Spyre Therapeutics Inc. is SYRE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top